N-Acylethanolamine-hydrolyzing acid amidase (NAAA) is a lysosomal enzyme that catalyzes the hydrolysis of endogenous fatty acid ethanolamides (FAEs), such as N-palmitoylethanolamide (PEA). PEA exhibits antiinflammatory and analgesic activities by engaging peroxisome proliferator-activated receptor a (PPAR-a). Preventing PEA degradation by inhibition of NAAA has been proposed as a novel strategy for the treatment of inflammation and pain. In the present study, we reported the discovery of the oxazolidone derivative as a novel scaffold for NAAA inhibitors, and studied the structure-activity relationship (SAR) by modification of the side chain and terminal lipophilic substituents. The results showed that the link chain length of C5, straight and saturated linkages were the preferred shape patterns for NAAA inhibition.
Introduction
N-Acylethanolamine-hydrolyzing acid amidase (NAAA) is a lysosomal cysteine hydrolase widely expressed in many tissues, especially those associated with immune responses, such as the lungs, spleen, and small intestine. NAAA participates in the control of inammatory and pain 1 via involving in the hydrolysis of endogenous palmitoylethanolamide (PEA). PEA is a multifunctional lipid mediator that has been shown to inhibit peripheral inammation [2] [3] [4] and cell degranulation, and exhibits antinociceptive activities in rat and mouse models of acute and chronic pain. [5] [6] [7] Moreover, PEA also could alleviate skin inam-mation 8 and neuropathic pain in humans. 9 Those effects are mainly attribute to the ability of PEA to engage nuclear receptor peroxisome proliferator-activated receptor-alpha (PPAR-a). In recent years, PEA has attracted increasing attention because of its potential therapeutic effects in inammation and pain. Preventing PEA degradation by inhibition of NAAA 10 may provide a novel strategy for the treatment of inammatory and pain. 4, 11 For this reason, NAAA has been pursued as a potential drug target.
Despite the increasing interest in the design of NAAA inhibitors as anti-inammatory and analgesic agents, only few potent NAAA inhibitors have been identied so far. 12, 13 There are two main categories of NAAA inhibitors reported, irreversible covalent inhibitors, such as b-lactone derivatives [14] [15] [16] [17] [18] and noncovalent reversible inhibitors, such as benzothiazole-piperazine derivatives. 19 Although covalent inhibitors, such as (S)-OOPP, 4 ARN077, 11 ARN726 (ref. 20) (Fig. 1 ) demonstrated profound antiinammatory effects in several animal models, their application is limited due to the poor chemical and plasma stability. These compounds degraded in phosphate buffered saline (PBS) within 120 min and were rapidly cleaved in plasma. 16 Non-covalent reversible inhibitors, such as, benzothiazole-piperazine derivatives ( Fig. 1) , 19 are selective, reversible, and competitive NAAA inhibitors. However, only few potent reversible NAAA inhibitors with drug-like properties have been identied so far. Highly potent, stable and reversible NAAA inhibitors are still highly desired for the treatment of inammation and pain.
In our previous study, we designed pyrrolidine-based derivatives 1a and 1b ( Fig. 1) 21 as NAAA inhibitors. Substitution of the saturated alkyl chain of 1a with an aryl-containing lipophilic moiety leaded to a potent NAAA inhibitor 1b (IC 50 ¼ 2.1 mM). In vivo pharmacological studies indicated that 1b reduced the mRNA expression levels of inducible nitric oxide synthase and interleukin-6, as well as increased the intracellular PEA levels in mouse macrophages with lipopolysaccharide-induced inam-mation. 21 Moreover, 1b exhibited excellent chemical stability and plasma stability (t1 2 > 16 h). In the present study, we further modied 1a to obtain more potent and biologically stable NAAA inhibitors. A nanomolar NAAA inhibitor 2f was discovered (IC 50 ¼ 270 nM), which exerted profound anti-inammatory and anti-nociceptive effects in rats. 22 We then carried out structure-activity relationship (SAR) studies on 2f by modication of the pyrrolidine ring and the lipophilic chain, which led to the identication of several more potent nanomolar NAAA inhibitors, such as 3h, 3i and 3j (Fig. 2) . Compound 2f was then selected as a model molecule to study the NAAA inhibition mechanisms and in vivo anti-inammatory and analgesic activities of oxazolidone derivatives. The results showed that 2f inhibited NAAA in a selective and highly reversible pattern, and efficiently reduced inammatory and pain aer systemic and oral administration. Oral administration of 2f (30 mg kg À1 ) exhibited the same efficacy with commercial nonsteroidal anti-inammatory drug ibuprofen at a 6.7-fold higher dose (200 mg kg À1 ).
Results and discussion

Synthesis of oxazolidone derivatives
First, we synthesized a series of oxazolidone derivatives with different side chains and terminal lipophilic substituents.
Compounds 1a, 1j-1o, and 1q-1t were prepared by the amidation of palmitoyl chloride with the corresponding amine in the presence of triethylamine (Scheme 1). 21 1l and 1m were prepared by the methylation of 1q and 1r with iodomethane in the presence of sodium hydride, respectively (Scheme 2).
23 1p was prepared by Dess-Martin periodinane oxidation of 1j or 1k (Scheme 3).
24 1c and 1d were prepared by the acidic deprotection of pyrrolidine derivatives 1c-1 and 1d-1, which were obtained by the amidation of (R)-or (S)-3-(tert-butoxycarbonylamino)pyrrolidine with palmitoyl chloride, respectively (Scheme 4). 25, 26 1e and 1f were synthesized by a two-step reaction starting from 1q and 1r, which were converted to iodide derivatives by I 2 and PPh 3 , respectively, followed by hydrogenation with H 2 (Scheme 5).
27,28 1g, 2a-2h, 3a-3d and 3k-3s were synthesized by the imidate reaction, employing the corresponding acyl chloride with 2-pyrrolidone, 2-imidazolidone, or 2-oxazolidone in the presence of n-BuLi, respectively (Scheme 6).
29 3e-3g were synthesized by the amidation of 2-oxooxazolidine-3-carbonyl chloride, generated by reaction of 2-oxazolidone and bis(trichloromethyl) carbonate, with the corresponding substituted piperazine or piperidine (Scheme 7).
30
HPLC analysis indicated >99% purity for compound 1g, 1e-1i, 2b, 2d, 2f-2h, 3c, 3e, and 3g, >98% purity for 1c-1d, 1f, 2a, 2e, 3a, 3b and 3g-3i, and >97% purity for 2c and 3d (Table S3 †).
NAAA inhibition by oxazolidone derivatives
The NAAA inhibition capability of these newly synthesized compounds were tested using heptadecenoylethanolamide as a substrate. Since many NAAA inhibitors also block fatty acid amide hydrolase (FAAH), the FAAH inhibition of these compounds also was examined to obtain NAAA selective inhibitors. (S)-OOPP and well known FAAH inhibitor URB597 were used as standard compounds in the enzymatic assay. The results showed that substitution at 3-position of pyrrolidine with an amino group (1c, 1d) slightly increased NAAA and FAAH inhibition, and substitutions at the 2-position with (S)-methyl (1f) or carbonyl (1g) slightly or moderately enhanced inhibition towards NAAA without changing inhibition against FAAH. However, (R)-methyl (1e), hydroxy (1j, 1k), methoxy (1l, 1m), cyano (1n), formamide (1o), hydroxymethyl (1q, 1r) and methoxymethyl (1s, 1t) substituents diminished the NAAA and FAAH inhibitory effects (Table S1 †). 1g exhibited lowmicromolar inhibition on NAAA activity (IC 50 ¼ 4.6 AE 0.48 mM), and it was over 5-fold more potent towards NAAA than FAAH (Table 1) . To further optimize the hydrophilic moieties, a series of 1g isosteres were synthesized and tested (1h, 1i) ( Table 2 ). Enzymatic assay results showed that 1i with oxazolidone ring had similar effects on NAAA inhibition as 1g, but 1i exhibited dramatically enhanced selectivity towards NAAA. Less than 10% FAAH activity was inhibited by 1i even at a concentration of 100 mM. Therefore, 2-oxazolidone ring was selected as the template for further optimization. It has been reported that substitutions of the saturated alkyl chain with aryl-containing lipophilic moieties could enhance the inhibitory potency on NAAA and improved the drug-like properties.
14,21 Therefore, a series of oxazolidone derivatives incorporating a phenyl ring at the terminus were synthesized and tested. As shown in Table 3 , 2a with the chain length of C0 exhibited low-micromolar inhibitory potency toward NAAA (IC 50 ¼ 3.4 AE 0.42 mM), while 2f with the chain length of C5 exhibited excellent potency (IC 50 ¼ 0.27 AE 0.04 mM), 3-fold more potent than (S)-OOPP tested under the same experimental conditions. Interestingly, sharply reduced or even abolished activity was observed as the chain length decreased from C5 to C1 or increased from C5 to C7. We are not quite sure why their potency dramatically changed when we varied the link chain length, probably because these oxazolidone imides with different chain length are activated to different extent when contacting the NAAA.
To further optimize the NAAA inhibition activity of 2f, we replaced the rotatable bond of the acyl chain of 2f with an additional phenyl group. As shown in Table 4 and S2, † a series of analogs corresponding to biphenyl (3a, 3k-3m), phenoxyphenyl (3b, 3n-3p), and benzyloxyphenyl (3c, 3q-3s) were obtained and examined. Compared to 2a, 1,4-substituted phenoxyphenyl (3b, IC 50 ¼ 0.68 AE 0.11 mM) and benzyloxyphenyl (3c, IC 50 ¼ 2.3 AE 0.36 mM) analogs were approximately 10-fold and 2-fold more potent. However, 1,4-substituted bipheny analog 3a (IC 50 ¼ 9.4 AE 1.2 mM) was 2-fold less potent (Table 4) , and 1,3-substituted isomers (3k, 3l, 3n, 3o, 3q, 3r) were completely inert for NAAA inhibition (Table S2 † ). The results indicated that straight structures are preferred shape for the hydrophobic channel of NAAA, which is in agreement with previous reports. 14,17 The binding pocket of NAAA proximal to the carbonyl moieties seemed to be narrow, as such, only a phenyl moiety is tolerated at this region. Therefore, incorporation of an extra methylene group between the biaryl and carbonyl groups (3m, 3p and 3s) signicantly decreased NAAA inhibition.
It's worth noting that the position of the terminal phenyl groups in biaryl series compounds (3a-3d) is corresponding to the location of phenyl moieties in the phenylalkyl series compounds (2e-2h). Increasing the length of the terminal aryl group of 3a by insertion of an oxygen atom or a methyleneoxy unit between the phenyl rings led to 14-fold (3b) or 4-fold (3c) higher potency, whereas the insertion of an additional methylene unit to the aliphatic linker of 3c signicantly decreased activity (3d). These results highlighted the importance of the optimal length and connecting pattern of the arylcontaining lipophilic moieties.
It has been reported that NAAA prefer saturated substrates e.g., N-myristoylethanolamine and PEA, rather than unsaturated substrates, e.g., AEA.
1 Therefore, we studied whether the replacement of a phenyl ring with a 6-member ring can improve the NAAA inhibition. A series of additional derivatives of 2f were then synthesized and examined (Table 5 ). The results showed that introducing hexane ring further enhanced the NAAA inhibitory potency. We found two highly potent NAAA inhibitors 3h and 3i with a IC 50 value of 150 nM and 100 nM, respectively, around 2-fold more potent than 2f. Moreover, saturated linkages were found to be more benecial for the activity than unsaturated benzene ring (3h, 3i vs. 3a-3c; 3j vs. 2f). However, nitrogen atoms substitution of the saturated hexane signi-cantly reduced the activity (3e-3g).
NAAA inhibition pattern
To further understand the NAAA inhibition pattern of these oxazolidone derivatives, compound 2f was selected as a model 
In vivo anti-inammatory and analgesic activities of 2f
Finally, the in vivo anti-inammation and analgesic activities of 2f was studied in different pain and inammation mice models. Experimental mice were treated with 2f via intraperitoneal injection or intragastrical administration. The behavioural response of Mice to formalin stimulation was divided to the rst-phase of acute pain (0-10 min) and the second-phase of chronic pain (15-35 min) . Single treatment of 2f (10 mg kg À1 , i.p.) decreased second-phase but not rst-phase (Fig. 4) , suggesting a central mechanism of action of 2f. over, 2f signicantly prevent the production of proinammatory cytokines, including TNF-a, IL-6, COX-2 and NF-kB in mRNA level (Fig. 5) . For many nonsteroidal anti-inammatory drugs, such as COX-2 inhibitors, adverse gastrointestinal effects and increased cardiovascular risks are two main limitations for their clinical application. We tested the toxicity of 2f by monitoring its inuence on food intake, body weight and ether-a-go-go-relatedgene (hERG) channel activity. Long-term studies suggested that intragastrical administration of 2f (30 mg kg À1 for 30 days, 100 mg kg À1 for 10 days) had no signicant effects on food intake and body weight in mice (Fig. S2 †) . Mice stomach anatomy indicated that 2f did not cause gastrointestinal hemorrhages, while indomethacin (20 mg kg À1 for 3 days, ig) resulted in obvious hemorrhages (Fig. S3 †) . The low gastrointestinal side effects of 2f may be because it induces analgesia and anti-inammatory via enhancement of PEA rather than reducing prostaglandins (PGs) in the gut. Moreover, the activity of hERG channels in CHO cells was only inhibited by 38.3% by 40 mM 2f (Fig. S4 †) , a concentration far above its threshold for NAAA inhibition. However, cisapride, a COX-2 inhibitor, inhibited 50% hERG at a concentration of 0.1 mM. These results suggested that with lower gastrointestinal and cardiovascular side effects, oxazolidone derivatives are promising antiinammatory drug candidates in clinical translation.
Conclusion
In conclusion, we report the discovery of oxazolidone derivatives as a novel scaffold of NAAA inhibitors. The NAAA inhibition activity of oxazolidone derivatives was modulated by the side chain and terminal lipophilic substituents. The results showed that the link chain length of C5, straight and saturated linkages were the preferred shape patterns. Several nanomolar NAAA inhibitors (2f, 3b, 3h, 3i and 3j) were developed. Compound 2f exhibited highly potent and selective inhibitory activity towards NAAA via a competitive and reversible pattern. Moreover, in vivo study showed that 2f had signicant antiinammatory and analgesic effects with low side effects. Our study demonstrated that oxazolidone derivatives is a class of potent NAAA inhibitors holds great promise for clinical translation. We anticipate that these oxazolidone derivatives will help better understand the function of NAAA and facilitate the development of improved therapies for inammation and pain.
Materials and methods
Materials and instruments
All reagents used in the present study were purchased from Sigma-Aldrich (Shanghai, China) unless otherwise indicated. 4 Si as internal substance. IR spectra were recorded on a Nicolet Avatar 360 RT-IR spectrophotometer. Mass spectra were recorded on an Applied Bio systems MDS SCIEX 3200Q-TRAP mass spectrometry (MS) system with electro spray ionization (ESI †) and direct injection. The HRFABMS spectra were recorded on a Bruker APEX-FTMS apparatus. Elemental analysis was performed using a Vario RL analyzer. Melting points were determined on a Yanaco MP-500 melting point apparatus and are uncorrected. HPLC analysis were run on Agilent-1200 series HPLC system equipped with a photodiode array detector, using a Hypersil Gold C18 column (dimensions 250 Â 4.6 mm, particle size 5 mm). Photodiode array (PDA) detector range was set as 210-600 nm.
Synthesis of oxazolidone derivatives
4.2.1 Synthesis of amides 1a, 1j, 1k, 1n, 1o and 1q-1t. Palmitoyl chloride (83 mg, 0.3 mmol) in CH 2 Cl 2 (2 mL) was added dropwise to a mixture of amine (0.3 mmol) and Et 3 N (0.08 mL, 0.6 mmol) in anhydrous CH 2 Cl 2 (2 mL) under a nitrogen atmosphere. The resulting solution was stirred at room temperature for 4 h, then quenched with saturated aqueous Vehicle, 0.1% DMSO; TPA, 0.03% in acetone. ### P < 0.001 vs. vehicle; * P < 0.1, ** P < 0.01, *** P < 0.001 vs. TPA control, n ¼ 8-10.
ammonium chloride, and extracted with CH 2 Cl 2 (3 Â 10 mL). The combined organic phases were washed with brine, dried over anhydrous Na 2 SO 4 , ltered, and concentrated under reduced pressure. The residue was puried by ash chromatography on silica gel and 1a, 1j, 1k, 1n, 1o and 1q-1t were then obtained. -1-yl)hexadecan-1-one (19 mg, 0 .06 mmol) in THF (1 mL) was added slowly to a suspension of NaH (60% in mineral oil, 5 mg) in anhydrous THF (5 mL), under a nitrogen atmosphere at 0 C. Aer stirring at the same temperature for 5 min, a solution of CH 3 I (0.15 mmol) in THF (0.5 mL) was slowly added. The reaction mixture was stirred at 0 C for 3 h before quenched with saturated aqueous ammonium chloride (5 mL) and extracted with EtOAc (3 Â 5 mL). The combined organic layers were treated using the same procedure as 2.2.1 to afford 1l and 1m. C. Aer stirring at the same temperature for 1 h, a THF solution (2 mL) of 1-(2-(hydroxymethyl) pyrrolidin-1-yl) hexadecan-1-one (71 mg, 0.2 mmol) was slowly added. The reaction mixture was stirred at 0 C for 0.5 h and allowed to warm slowly to room temperature over 2 h. The reaction was quenched with a saturated solution of Na 2 S 2 O 3 and extracted with EtOAc (3 Â 5 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 , ltered, and concentrated under reduced pressure. The mixture in EtOAc (10 mL) was treated with 10% Pd/C (100 mg) and purged with H 2 .
Aer stirring for 12 h at room temperature, the reaction mixture was ltered through celite and concentrated. The residue was puried by ash chromatography on silica gel (eluent : EtOAc/ PE 1 : 5) to afford 1e and 1f. was slowly added. The reaction mixture was stirred at À78 C for 0.5 h and allowed to warm slowly to room temperature over 5 h. The reaction was quenched with saturated aqueous ammonium chloride (1.0 mL) and extracted with EtOAc (3 Â 5 mL). The combined organic layers were treated using the same procedure as 2.2.1 to afford 1i, 2a-2h, 3a-3d and 3h-3s. 29 4.2.6 Synthesis of acids 3q-1 and 3t-1. Thionyl dichloride (0.2 mL, 3 mmol) was slowly added to 10 mL CH 3 OH solution of the corresponding carboxylic acid (2.0 mmol) under a nitrogen atmosphere at 0 C. The reaction mixture was stirred at 0 C for 2 h and evaporated under reduced pressure. The product was dissolved in acetone (15 mL) and treated with K 2 CO 3 (552 mg, 4 mmol) and alkyl bromide (2.5 mmol). The reaction mixture was ltered and concentrated under reduced pressure aer being reuxed for 8 h. The residue was dissolved in a 1 : 1 mixture of aqueous 2 M NaOH and MeOH (16 mL), stirred at room temperature for 4 h, then treated with 2 M HCl, and extracted with EtOAc (3 Â 5 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 , ltered, and concentrated under reduced pressure. The residue was puried by ash chromatography on silica gel to afford 3q-1 and 3t-1. The resulting mixture was stirred at room temperature for 5 h, quenched with saturated aqueous ammonium chloride, and extracted with CH 2 Cl 2 (3 Â 10 mL). The combined organic phases were washed with brine, dried over anhydrous Na 2 SO 4 , ltered, and concentrated under reduced pressure. The residue was puried by ash chromatography on silica gel to afford 3e-3g. 21 Briey, samples containing 100-fold concentrated rNAAA protein were pre-incubated with 10-fold of the IC 50 -equivalent concentration of compounds or vehicle (1% DMSO) for 10 min at 37 C. The samples were then diluted 100-fold with assay buffer containing substrate to initiate the reactions, and the time course of product formation was determined by HPLC-MS analysis.
In vivo anti-inammatory and analgesic activity of compound 2f
All animal experiments were performed in accordance with 'Guide and Care and Use of Laboratory Animals' from National Institutes of Health (NIH) and approved by the Animal Care and Use Committees of Xiamen University in China. 4.4.1 In vivo analgesic activity of compound 2f. Formalininduced pain model was used to evaluate the in vivo analgesic activity of 2f. Male ICR mice (18-20 g ) were allowed to acclimate to the Plexiglas chamber for 30 min before testing. Compound 2f (10 mg kg À1 , dissolved in 5% polyethylene glycol 400 and 5%
Tween-80 in saline) was then injected into the plantar surface of the right hind paw with or without PPAR-a antagonist MK886 (2 mg kg À1 ). Aer 30 min, formalin (20 mL of 5% formalin, diluted in saline) was injected into the dorsal surface of the right hind paw and pain responses were recorded by an automated detecting system. The paw licking time was calculated every 5 min over the next 45 min. Nociceptive behavioural response to formalin stimulation was dened as follows: Phase I (0-10 min), acute pain response, Phase II (11-45 min), chronic pain response.
4.4.2
In vivo anti-inammatory activity of compound 2f. TPA-induced ear edema model was used to test the antiinammatory of compound 2f. Male WT 129s mice (20-22 g) were grouped randomly, with 8-10 animals for each group. Compound 2f (30, 100 mg kg À1 ) was then administered by intragastric gavage 30 min before TPA application. TPA (0.03% in acetone, 10 mL) was applied evenly to both sides of the le ear of each mouse to cause edema and inammation, while the same amount of acetone alone was smeared to the right ear. Animals were sacriced 3 h aer treatment. Both ears were excised immediately and punched in the same position, with a diameter of 9 mm. The ear swelling was determined by weighing pieces of the ears obtained. The mRNA expression levels of TNF-a, IL-6, COX-2 and NF-kB in mice ear were determined following our previously reported method. 
